SUBSCRIBE
SUBSCRIBE
News   Deals

MDRNA, Inc. Gets Full Control Over its Gene Technology from RiboTask ApS

June 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- MDRNA Inc. said it gained full financial and transactional control over the use of its technology for the development of RNAi, or gene silencing-based, therapeutics from RiboTask ApS.

Mergers & acquisitions
MORE ON THIS TOPIC
Pictured: Eli Lilly's biotechnology center in California
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
June 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
People walking around a convention center
Editorial
The Decadent Show of Data at ASCO25
June 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Fantasy background for poster for tourism company. Illustration of stormy sea waves with ancient sailboat Spanish galleon and lighthouse at night. Modern print. Vector cartoon image.
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
June 2, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Abstract handshake
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
June 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor